Oncodesign and LNGT: research collaboration for advancing drug discovery efforts with Ipsen in Parkinson's disease
“This collaboration with Oncodesign is a perfect example of translational research in action,” said Veerle Baekelandt, Ph.D., principle investigator of LNGT. “Parkinson’s disease has been the focus of our research for more than ten years now. We are very pleased that Oncodesign has selected our lab as a partner for advancing their kinase program,” she added.
Under the terms of the agreement, Oncodesign and LNGT will closely collaborate to advance Oncodesign's Parkinson’s disease program towards clinical development. LNGT will receive full financial support from Oncodesign for these activities.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.